References
Pruzanski W, Katz A (1984) Cold agglutinins-antibodies with biological diversity. Clin Immunol Rev 3:131–168
Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjonnfjord GE (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103:2925–2928
Rosse WF, Adams JP (1980) The variability of hemolysis in the cold agglutinin syndrome. Blood 56:409–416
Petz LD (2008) Cold antibody autoimmune hemolytic anemias. Blood Rev 22:1–15
Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, Jensen BA, Pedersen BB, Taaning EB, Klausen TW, Birgens H (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 47:253–260
Salama A, Göttsche B, Vaidya V, Santoso S, Mueller-Eckhardt C (1988) Complement-independent lysis of human red blood cells by cold hemagglutinins. Vox Sang 55:21–25
Berentsen S, Beiske K, Tjonnfjord GE (2007) Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology 12:361–370
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hattori, N., Ishii, N., Ariizumi, H. et al. Improvement of the thermal amplitude after rituximab treatment for cold agglutinin disease with Waldenström’s macroglobulinemia. Ann Hematol 89, 103–104 (2010). https://doi.org/10.1007/s00277-009-0773-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-009-0773-z